UK's Creo Medical H1 revenue surges, loss narrows

By Reuters News


Overview

  • UK medical device firm's H1-26 revenue rose 45% yr/yr, in line with management expectations

  • Underlying operating loss for H1-26 narrowed by over 25% to £4.9 mln

  • Company completed £5.5 mln equity placing and secured £2 mln convertible loan note in May 2026


Outlook

  • Creo Medical expects full-year revenue growth of 50% to 60%

  • Company says H2 revenue profile is supported by a strong order book and usual seasonality

  • Company expects proceeds from CME Stake Disposal to strengthen near-term balance sheet


Result Drivers

  • PROCEDURAL ADOPTION - Co said revenue growth was supported by increased adoption of its advanced energy platform and broader clinician engagement

  • COST CONTROL - Co attributed reduced operating costs to disciplined cost control and a simplified operating model

  • CLINICAL VALIDATION - Co said growing external clinical validation and key opinion leader presentations supported commercial adoption


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Underlying EBIT on contops basis

-GBP 4.9 mln


Analyst Coverage

  • The one available analyst rating on the shares is "strong buy"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Creo Medical Group PLC is GBp55.00, about 363.2% above its September 29 closing price of GBp11.88


Reuters Recommended Reads

  • Sept 29 - UK's Billington Holdings H1 profit jumps 70% on data centre demand

  • Sept 28 - Betting firms Flutter and Entain warn of hit from Brazil's online betting ban

  • Sept 28 - Tullow Oil swings to positive free cash flow as Ghana output, higher oil prices drive growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.